NuSep licences gels

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.

The third party had offered to acquire NuSep's gels business outright or to license the technology.

It was decided that licensing the technology would provide the best return for shareholders, the company said.

The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.

NuSep also supplies research grade biological products such as human IgG and albumin.

Related News

Anti-inflammatory drug may help treat alcohol use disorder

A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...

Osteoarthritis study uncovers new genetic links, drug targets

The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...

How brain cells are affected by Tourette syndrome

US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd